Printer Friendly

CAMBRIDGE BIOTECH ANNOUNCES POSITIVE IMMUNOSTIMULATIVE RESULTS FOR STIMULON ADJUVANT IN MELANOMA TRIALS AT MEMORIAL SLOAN-KETTERING

 /Repeating to correct garble in first line of second paragraph/
 WORCESTER, Mass., Oct. 11 /PRNewswire/ -- Recently published data from the New York Academy of Sciences indicate that Cambridge Biotech Corporation's (NASDAQ: CBCX) Stimulon adjuvant was effective in provoking a higher and longer-lasting antibody response than other adjuvants tested in a study on 18 post-surgical melanoma patients at Memorial Sloan-Kettering Cancer Center. The results were announced in Specific Immunotherapy of Cancer with Vaccines, Vol. 690, 1993.
 The double-blind randomized study was conducted by Dr. Philip O. Livingston. Three groups of six patients each were given injections of a conjugated melanoma ganglioside. Adjuvants were added to the formulations when it was found that the ganglioside alone was not able to provoke an adequate immune response. One group of six patients was given no adjuvant; one group was given antigen in combination with DETOX (Ribi ImmunoChem); the third group was given antigen in combination with Stimulon QS-21. All six of the group given Stimulon QS-21 demonstrated positive IgG response; only one participant out of the 12 in both other groups demonstrated any increase in IgG antibody titers.
 Dr. Livingston noted that "the addition of the immunological adjuvant DETOX augmented the IgM antibody response slightly but had no significant impact on IgG antibody titers. (Stimulon) QS-21, however, significantly augmented the IgM response beyond that seen with other adjuvants and induced a consistent IgG antibody response in all patients....The IgM antibodies were of higher titer and longer duration."
 These results provide the foundation for further trials beginning in late 1993. Vaccinations in these trials will continue at 4-6 month intervals for four years.
 Adjuvants are key components of vaccines that boost ability to elicit strong responses from the immune system. Like the microprocessor chip in a computer, the adjuvant functions as a driving force within the vaccine, increasing its ability to prevent and treat disease. Cambridge Biotech's Stimulon QS-21 adjuvant holds the promise of being a "universal adjuvant" that enhances existing vaccines and makes new generation vaccines possible.
 Cambridge Biotech Corporation is a leading diagnostics and therapeutics company involved in infectious diseases. The company is developing vaccines, adjuvants and diagnostics for humans and animals.
 -0- 10/11/93 R
 /CONTACT: Alyson Button Stone, coordinator of investor relations of Cambridge Biotech Corporation, 508-797-5777, ext. 541/
 (CBCX)


CO: Cambridge Biotech Corporation ST: Massachusetts IN: MTC SU:

GK -- NY001R -- 0649 10/11/93 11:31 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 11, 1993
Words:399
Previous Article:VIEWLOGIC ADDS VHDL SIMULATION, SYNTHESIS TO LOW-COST PRO SERIES EDA PRODUCT LINE; NEW MODULES CREATE FIRST WINDOWS TOP-DOWN DESIGN SOLUTION
Next Article:ACF INDUSTRIES, ACF INDUSTRIES HOLDING WON'T PROCEED WITH DEBT OFFERINGS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters